T 2589/16 (Cross-species CD3 antibody/AMGEN) of 16.11.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T258916.20211116
- Date of decision
- 16 November 2021
- Case number
- T 2589/16
- Online on
- 22 April 2022
- Petition for review of
- -
- Application number
- 08735001.3
- IPC class
- C07K 16/28A61P 31/14C07K 14/705C07K 16/10A61P 35/00A61K 39/395C07K 16/32A61P 35/02C07K 16/46C07K 16/42C07K 16/30A61P 31/12C07K 16/08
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Cross-species-specific CD3-epsilon binding domain
- Applicant name
- Amgen Research (Munich) GmbH
- Opponent name
- Janssen Biotech, Inc.
F.Hoffmann-La Roche AG
Engmab AG
Genmab A/S
Affimed GmbH (opposition withdrawn)
Chugai Seiyaku Kabushiki Kaisha
Pfizer Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 87Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)
- Keywords
- Late-filed main request and auxiliary requests 20A, 20B, 20C, 20D
Late-filed auxiliary requests - admitted (no)
Auxiliary request 21 - Priority - same invention (yes); Amendments - allowable (yes); Sufficiency of disclosure - (yes); Inventive step - (yes)
Late-filed objection - submitted during oral proceedings
Late-filed objection - admitted (no)
Late-filed objection - inadequately substantiated
Late-filed objection - admitted (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed.